Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
Parkinsonism & Related Disorders|September 27, 2025
Objective real-world mobility patterns in Parkinson's disease: Driving and walking after levodopa dosingJun Ha Chang, Ergun Y Uc, Christopher L Shaffer, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 23, 2006
Using a tritiated compound to elucidate its preclinical metabolic and excretory pathways in vivo: exploring tritium exchange riskChristopher L Shaffer, Mithat Gunduz, Bruce A Thornburgh, et al.Biopharmaceutics & Drug Disposition|January 4, 2012
Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse eventsChristopher L Shaffer, Renato J Scialis, Haojing Rong, et al.Journal of Pharmaceutical Sciences|March 18, 2014
Diphenhydramine has similar interspecies net active influx at the blood-brain barrierChristopher L Shaffer, Sarah M Osgood, Jessica Y Mancuso, et al.Pharmacotherapy|March 11, 2015
Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective studyKelly L Matson, Christopher L Shaffer, Gary L Beck, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 18, 2012
An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrationsAngela C Doran, Sarah M Osgood, Jessica Y Mancuso, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 9, 2008
Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humansChristopher L Shaffer, Mithat Gunduz, Alfin D Vaz, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 6, 2005
Biotransformation of a GABAA receptor partial agonist in sprague-dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolitesChristopher L Shaffer, Mithat Gunduz, Thomas N O'Connell, et al.Expert Opinion on Drug Discovery|June 1, 2012
Strategies to optimize the brain availability of central nervous system drug candidatesTravis T Wager, Anabella Villalobos, Patrick R Verhoest, et al.Journal of Neuroscience Methods|February 20, 2013
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scaleSubramaniam Uthayathas, Christopher L Shaffer, Frank S Menniti, et al.Pageof 5